ARTICLE | Regulation
ICER panel unanimously rebuffs Aduhelm
Vote comes as health systems decline to administer the Alzheimer’s therapy
July 16, 2021 12:02 AM UTC
In another setback for Biogen and Eisai, ICER’s California Technology Assessment Forum on Thursday voted 15-0 that the evidence is not adequate to demonstrate the net health benefit of Aduhelm plus supportive care is superior to supportive care alone.
An ICER report issued in June said Biogen’s list price for Aduhelm aducanumab-avwa would only be cost-effective for a drug that completely halted disease progression. ICER had calculated an annual fair price of $2,500-$8,300 for Aduhelm before the drug’s accelerated approval for Alzheimer’s, far below its annual price tag of $56,000. ...